Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Zhu Zeng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-3520-5783; OpenAlex author ID A5006411450. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper

Papers 16

  1. tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription. Co-author DOI 10.1038/s41388-024-02991-9↗
  2. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Co-author DOI 10.1002/cam4.5774↗
  3. Metabolic stress-induced reciprocal loop of long noncoding RNA ZFAS1 and ZEB1 promotes epithelial-mesenchymal transition and metastasis of pancreatic cancer ce… First author DOI 10.1111/cas.15905↗
  4. A reciprocal feedback between N6-methyladenosine reader YTHDF3 and lncRNA DICER1-AS1 promotes glycolysis of pancreatic cancer through inhibiting maturation of … Co-author DOI 10.1186/s13046-022-02285-6↗
  5. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Co-author DOI 10.1038/s41388-021-01960-w↗
  6. LncRNA ZNFTR functions as an inhibitor in pancreatic cancer by modulating ATF3/ZNF24/VEGFA pathway. Co-author DOI 10.1038/s41419-021-04119-3↗
  7. LncRNA-ZFAS1 Induces Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells During Nutrient Deprivation by Promoting AMPK-Mediated Phosphorylation and St… Co-author DOI 10.21203/rs.3.rs-875697/v1↗
  8. Positive Reciprocal Feedback of lncRNA ZEB1-AS1 and HIF-1α Contributes to Hypoxia-Promoted Tumorigenesis and Metastasis of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.761979↗
  9. Corrigendum: Positive Reciprocal Feedback of LncRNA ZEB1-AS1 and HIF-1α Contributes to Hypoxia-Promoted Tumorigenesis and Metastasis of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.821077↗
  10. A reciprocal feedback of Myc and lncRNA MTSS1-AS contributes to extracellular acidity-promoted metastasis of pancreatic cancer. Co-author DOI 10.7150/thno.49147↗
  11. Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-0419↗
  12. Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Co-author DOI 10.7150/thno.30988↗
  13. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Co-author DOI 10.7150/thno.34559↗
  14. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Co-author DOI 10.1038/s41388-017-0082-2↗
  15. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Co-author DOI 10.1038/s41388-018-0382-1↗
  16. MiR-548an, Transcriptionally Downregulated by HIF1α/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression. Co-author DOI 10.1158/1535-7163.mct-15-0877↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fengyu Xu · 9 shared papers, 2018–2022 · strength 0.89
  2. Gang Zhao · 10 shared papers, 2016–2021 · strength 0.87
  3. Yuhang Hu · 6 shared papers, 2019–2022 · strength 0.65
  4. Chunyou Wang · 7 shared papers, 2016–2021 · strength 0.53
  5. Ye Zeng · 6 shared papers, 2018–2021 · strength 0.49
  6. Shi-Jiang Deng · 6 shared papers, 2016–2019 · strength 0.44
  7. Mingliang Liu · 6 shared papers, 2016–2019 · strength 0.44
  8. Shuai Zhu · 5 shared papers, 2016–2021 · strength 0.37
  9. Qunli Xiong · 2 shared papers, 2023–2024 · strength 0.36
  10. Yongfeng Xu · 2 shared papers, 2023–2024 · strength 0.36
  11. Qing Zhu · 2 shared papers, 2023–2024 · strength 0.36
  12. Wenfeng Zhuo · 2 shared papers, 2022–2023 · strength 0.29
  13. Yabin Xia · 2 shared papers, 2021 · strength 0.27
  14. Shichang Deng · 4 shared papers, 2016–2019 · strength 0.27
  15. Wei Li · 2 shared papers, 2020–2021 · strength 0.21
  16. Peng Xu · 2 shared papers, 2020–2021 · strength 0.19
  17. Ying Zheng · 1 shared paper, 2024 · strength 0.18
  18. Zhiwei Zhang · 1 shared paper, 2024 · strength 0.18
  19. Jinlu Liu · 1 shared paper, 2024 · strength 0.18
  20. Congya Zhou · 1 shared paper, 2023 · strength 0.18
  21. Yang Yang · 1 shared paper, 2023 · strength 0.18
  22. Jie Wang · 1 shared paper, 2023 · strength 0.15
  23. Gang Zhao · 1 shared paper, 2023 · strength 0.15
  24. Qiang Li · 2 shared papers, 2018–2019 · strength 0.15
  25. Gang Zhao · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.